-
Je něco špatně v tomto záznamu ?
Vichy mineralizing water with hyaluronic acid is effective and well tolerated as an adjunct to the management of various dermatoses and after esthetic procedures
J. Tan, J. Spada, C. Orlandi, M. Kerscher, M. Anfilova, S. Abdulla, A. Floriánová, K. Preisz, A. Altmayer, C. Delva, D. Kerob, M. Goldobina, M. Arenbergerová, S. Tuz, E. Araviiskaia,
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, multicentrická studie
Grantová podpora
Laboratoires Vichy International
PubMed
31793738
DOI
10.1111/jocd.13229
Knihovny.cz E-zdroje
- MeSH
- aplikace kožní MeSH
- dospělí MeSH
- kombinovaná terapie metody MeSH
- kosmetické přípravky aplikace a dávkování škodlivé účinky chemie MeSH
- kosmetické techniky škodlivé účinky MeSH
- kůže účinky léků MeSH
- kyselina hyaluronová aplikace a dávkování škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- minerální vody aplikace a dávkování škodlivé účinky MeSH
- obličej MeSH
- obličejové dermatózy etiologie terapie MeSH
- prospektivní studie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
INTRODUCTION: M89, containing 89% of Vichy mineralizing water and hyaluronic acid, has been developed to reinforce the skin barrier and to improve skin quality. AIM: To assess efficacy and tolerability of M89. METHOD: Observational survey of subjects with facial dermatoses or after esthetic procedures. M89 served as adjunct to conventional therapy. Clinician assessments of erythema, desquamation, irritation and patient-reported dryness, burning, itching, and stinging/tingling were conducted at baseline and 4 weeks. At 1 week and 4 weeks, patient assessed tolerance and satisfaction with M89. RESULTS: A total of 1630 subjects participated; 92.5% were females. Mean age was 41.1 ± 11.3 years. Dermatological indications accounted for 32.5%, procedures for 67.5%. At 4 weeks, in subjects with dermatoses, erythema had resolved or improved in 68.0%, desquamation in 83.4%, and irritation in 93.3%. Dryness, burning, itching, and stinging/tingling scores had decreased by 63.8%, 81.8%, 70.9%, and 85.2%, respectively (all P ≤ .0001); 75.7% considered that their skin was sufficiently hydrated. In the procedure group, erythema had resolved or improved in 72.5%, desquamation in 75.2%, and irritation in 88.1%. Dryness, burning, itching, and stinging/tingling scores had decreased by 62.1%, 78.8%, 70.0%, and 84.2%, respectively (all P ≤ .0001); 74.1% considered that their skin was sufficiently hydrated. Almost all subjects reported soothed skin and satisfaction with product texture. Subject and investigator satisfaction was very high. CONCLUSION: M89 significantly improves skin signs and symptoms after 4 weeks of continued use with no tolerance issues in subjects with dermatological indications. Moreover, subjects who have had recently undergone esthetic procedures M89 allowed a satisfying skin recovery.
Buda Health Centre Budapest Hungary
Clínica Dra Julieta Spada Dermatología y Estética Buenos Aires Argentina
Clinica Orlandi Santiago Chili
Department of Dermatology 1st Pavlov State Medical University of St Petersburg St Petersburg Russia
Department of Dermatology and Allergology Szent Györgyi Albert Clinical Centre Szeged Hungary
Dermatology on Bloor Toronto ON Canada
Division of Cosmetic Science University of Hamburg Hamburg Germany
Laboratoires Vichy International Lavallois Perret France
Private medical practice Saint Petersburg Russia
Private Practice TOMAR Bratislava Slovakia
Schulich School of Medicine and Dentistry Western University Windsor ON Canada
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028453
- 003
- CZ-PrNML
- 005
- 20210114153921.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/jocd.13229 $2 doi
- 035 __
- $a (PubMed)31793738
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Tan, Jerry $u Schulich School of Medicine and Dentistry, Western University, Windsor, ON, Canada.
- 245 10
- $a Vichy mineralizing water with hyaluronic acid is effective and well tolerated as an adjunct to the management of various dermatoses and after esthetic procedures / $c J. Tan, J. Spada, C. Orlandi, M. Kerscher, M. Anfilova, S. Abdulla, A. Floriánová, K. Preisz, A. Altmayer, C. Delva, D. Kerob, M. Goldobina, M. Arenbergerová, S. Tuz, E. Araviiskaia,
- 520 9_
- $a INTRODUCTION: M89, containing 89% of Vichy mineralizing water and hyaluronic acid, has been developed to reinforce the skin barrier and to improve skin quality. AIM: To assess efficacy and tolerability of M89. METHOD: Observational survey of subjects with facial dermatoses or after esthetic procedures. M89 served as adjunct to conventional therapy. Clinician assessments of erythema, desquamation, irritation and patient-reported dryness, burning, itching, and stinging/tingling were conducted at baseline and 4 weeks. At 1 week and 4 weeks, patient assessed tolerance and satisfaction with M89. RESULTS: A total of 1630 subjects participated; 92.5% were females. Mean age was 41.1 ± 11.3 years. Dermatological indications accounted for 32.5%, procedures for 67.5%. At 4 weeks, in subjects with dermatoses, erythema had resolved or improved in 68.0%, desquamation in 83.4%, and irritation in 93.3%. Dryness, burning, itching, and stinging/tingling scores had decreased by 63.8%, 81.8%, 70.9%, and 85.2%, respectively (all P ≤ .0001); 75.7% considered that their skin was sufficiently hydrated. In the procedure group, erythema had resolved or improved in 72.5%, desquamation in 75.2%, and irritation in 88.1%. Dryness, burning, itching, and stinging/tingling scores had decreased by 62.1%, 78.8%, 70.0%, and 84.2%, respectively (all P ≤ .0001); 74.1% considered that their skin was sufficiently hydrated. Almost all subjects reported soothed skin and satisfaction with product texture. Subject and investigator satisfaction was very high. CONCLUSION: M89 significantly improves skin signs and symptoms after 4 weeks of continued use with no tolerance issues in subjects with dermatological indications. Moreover, subjects who have had recently undergone esthetic procedures M89 allowed a satisfying skin recovery.
- 650 _2
- $a aplikace kožní $7 D000279
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a kombinovaná terapie $x metody $7 D003131
- 650 _2
- $a kosmetické techniky $x škodlivé účinky $7 D003357
- 650 _2
- $a kosmetické přípravky $x aplikace a dávkování $x škodlivé účinky $x chemie $7 D003358
- 650 _2
- $a obličej $7 D005145
- 650 _2
- $a obličejové dermatózy $x etiologie $x terapie $7 D005148
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kyselina hyaluronová $x aplikace a dávkování $x škodlivé účinky $7 D006820
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a minerální vody $x aplikace a dávkování $x škodlivé účinky $7 D008900
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a kůže $x účinky léků $7 D012867
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a multicentrická studie $7 D016448
- 700 1_
- $a Spada, Julieta $u Clínica Dra Julieta Spada. Dermatología y Estética, Buenos Aires, Argentina.
- 700 1_
- $a Orlandi, Cecilia $u Clinica Orlandi, Santiago, Chili.
- 700 1_
- $a Kerscher, Martina $u Division of Cosmetic Science, University of Hamburg, Hamburg, Germany.
- 700 1_
- $a Anfilova, Maryna $u Department of Dermatology and Venereology, Vinnytsya National Pirogov Memorial Medical University, Vinnytsya, Ukraine.
- 700 1_
- $a Abdulla, Sonya $u Dermatology on Bloor, Toronto, ON, Canada.
- 700 1_
- $a Floriánová, Adriana $u Private Practice TOMAR, Bratislava, Slovakia.
- 700 1_
- $a Preisz, Klaudia $u Buda Health Centre, Budapest, Hungary.
- 700 1_
- $a Altmayer, Anita $u Department of Dermatology and Allergology, Szent-Györgyi Albert Clinical Centre, Szeged, Hungary.
- 700 1_
- $a Delva, Catherine $u SyliaStat Lancrenon, Bourg-la-Reine, France.
- 700 1_
- $a Kerob, Delphine $u Laboratoires Vichy International, Lavallois Perret, France.
- 700 1_
- $a Goldobina, Maiia $u Private medical practice, Saint-Petersburg, Russia.
- 700 1_
- $a Arenbergerová, Monika $u Department of Dermato-venereology, Third Faculty of Medicine, Charles University, Královské Vinohrady University Hospital, Prague, Czech Republic.
- 700 1_
- $a Tuz, Svyatoslav $u Sharapova Clinic, Samara, Russia.
- 700 1_
- $a Araviiskaia, Elena $u Department of Dermatology, First Pavlov State Medical, University of St. Petersburg, St. Petersburg, Russia.
- 773 0_
- $w MED00007681 $t Journal of cosmetic dermatology $x 1473-2165 $g Roč. 19, č. 3 (2020), s. 682-688
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31793738 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153917 $b ABA008
- 999 __
- $a ok $b bmc $g 1608788 $s 1119633
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 19 $c 3 $d 682-688 $e 20191203 $i 1473-2165 $m Journal of cosmetic dermatology $n J Cosmet Dermatol $x MED00007681
- GRA __
- $p Laboratoires Vichy International
- LZP __
- $a Pubmed-20210105